IL21 and diabetes mellitus: IL-21 neutralisation has been shown to prevent diabetes in mice [60], and a C-peptide-sparing benefit of anti-IL-21 alone or in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) liraglutide has been observed in a clinical proof-of-concept study [61], as described further below.